Jobs
View more job listings or post a job
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Post a job

Symposium

[Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development


Speakers: Hongtao Zhao, AstraZeneca; Anil Vasudevan, AbbVie; Jesus Medina, Arvinas; Donglu Zhang, Genentech; Elisia Villemure, Genentech
Organizers: Elizabeth Kelley, PhD, Genentech; Wei Chen, PhD; Steven Richards, PhD.
Date: 2024-09-25- 9/25/2024
Time: 8:30-12:45 Pacific Time
Registration fee: Free
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-09-24  (it will close sooner if the seating cap is reached)

About the Topic

Targeting the destruction of proteins via a degradation mechanism of action has opened up the door to many targets that have proven difficult to drug via traditional inhibition mechanisms. Just as with traditional small molecule inhibitors or modulators, successful development of degraders requires support and collaboration from a variety of disciplines. This symposium will aim to cover not only specific medicinal chemistry development stories of degrader molecules of interest, but also emerging technologies in the fields of computational chemistry and DMPK that aid in the development of this novel class of therapeutic agents. Featuring all industrial speakers actively working in the degradation area, this symposium will be a highly practical look at how both smaller biotechs and larger pharmaceutical companies successfully execute to bring degraders to the clinic.

Time (PT) Topic Speaker
8:30-8:45 am PBSS Welcome and Introduction Elizabeth Kelley, PhD, Genentech
8:45-9:30 am Kinetic Modeling of PROTAC-Induced Protein Degradation Hongtao Zhao, PhD, Associate Principal Scientist, Computational Chemistry, AstraZeneca
9:30-10:15 am Degrader Efforts at AbbVie Anil Vasudevan, PhD, Executive Director, Senior Research Fellow, AbbVie
10:15-10:25 am Break -
10:25-11:10 am Discovery of Potent, Selective, and Efficacious KRAS-Targeted PROTAC Degraders Jesus Medina, PhD, Senior Director, Immunology/Immuno-oncology Chemistry, Arvinas
11:10-11:55 am Bi-functional Protein Degraders: Relatively Poor Pharmacokinetics and Delivery to the Site of Action Donglu Zhang, PhD, Staff Scientist, Genentech
11:55 am-12:15 pm Monovalent Degraders of SMARCA2/A4 (BRM/BRG1) Acting Through Recruitment of FBXO22 Elisia Villemure, MS, Principal Scientist, Genentech
12:15-12:45 pm Panel Discussion All Speakers


2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
©Pharmaceutical & BioScience Society, International; Last Modified: 7/24/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Simulations Plus GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad